Karina Hermosillo Reséndiz

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study

J. Schopohl, J. Bollerslev, A. Arafat, 2014, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

E. Wolin, V. Giannone, K. Hu, 2013, Cancer Chemotherapy and Pharmacology.

Pasireotide (SOM230), a Novel Multireceptor‐Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7‐Day Subcutaneous Infusion in Healthy Male Volunteers

K. Mann, Yilong Zhang, S. Petersenn, 2012, Journal of clinical pharmacology.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly

S. Melmed, J. Schopohl, P. Caron, 2018 .